@article{article, title  = {{Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial}},

 publisher = {{American Medical Association}},

 url = {{https://eprints.whiterose.ac.uk/id/eprint/145642 }},

 year = {{2019}},

 month = {{8}},

 author = {{Schmid P and Zaiss M and Harper-Wynne C and Ferreira M and Dubey S and Chan S and Makris A and Nemsadze G and Brunt A and Kuemmel S and Ruiz I et al}},

 doi = {{10.1001/jamaoncol.2019.2526}},

 volume = {{5}},

 journal = {{JAMA Oncology}},

 issue = {{11}},

 pages = {{1556-1564}},

 note = {{Accessed on 2025/11/03}}}